Objective:

To provide updated clinical practice guidelines for the treatment of Helicobacter pylori infections based on rising antibiotic resistance rates and new treatment regimens.

Approach:

• Guideline Development: The guideline panel utilized GRADE methodology to analyze 11 Population, Intervention, Comparison, and Outcome questions, generating recommendations based on evidence quality, risks vs benefits, feasibility, and costs.
• Literature Review: A comprehensive literature search was conducted across multiple databases, reviewing randomized controlled trials, systematic reviews, meta-analyses, and network meta-analyses.

Key Findings:

• Bismuth quadruple therapy (BQT) for 14 days is recommended as the preferred first-line treatment when antibiotic susceptibility is unknown.
• Rifabutin triple therapy (Omeprazole 10 mg, amoxicillin 250 mg, and rifabutin 12.5 mg; 4 capsules 3 times daily for 14 days) and potassium-competitive acid blocker (PCAB) dual therapy (Vonoprazan 20 mg twice daily and amoxicillin 1,000 mg 3 times daily for 14 days) are suitable alternatives for patients without penicillin allergy.
• Clarithromycin- and levofloxacin-containing regimens should be avoided without demonstrated susceptibility.
• Universal posttreatment testing for H pylori eradication is recommended at least 4 weeks after therapy completion.
• Optimized BQT for 14 days is preferred salvage therapy for treatment-experienced patients who have not previously received it.

Interpretation:

The guidelines highlight increasing H pylori resistance rates in North America, with significant regional variations. They emphasize the importance of posttreatment testing.

Limitations:

• The guidelines do not address the comparative effectiveness of new FDA-approved regimens in diverse North American populations.
• Knowledge gaps remain regarding optimal use of antibiotic susceptibility testing in clinical practice.

Conclusion:

The updated guidelines aim to improve treatment outcomes for H pylori infections amidst rising antibiotic resistance and provide evidence-based recommendations for clinicians.

Sources:

• American College of Gastroenterology Guidelines